Company Description
Hesperos, Inc. is a socially-conscious company that uses our non-invasive, serum-free, multi-organ chip platform (Human-on-a-Chip) systems to provide pre-clinical analytical services with the goal of accelerating drug discovery and general toxicology testing and reducing use of animal testing.
Our Human-on-a-Chip platform system mimics the process of initial patient evaluation during a clinical trial, where functional human in vitro tissues are evaluated similar to a patient undergoing medical testing to determine baseline performance metrics.
Specific screens for heart rate, respiration, basic cognitive function, reflex tests on muscle and nerve, elimination, and chemical screens for liver, kidney and hematopoietic function can be integrated into our unique pumpless platform.
If anything abnormal is observed, additional biomarkers are evaluated much like a blood test administered to a patient.
If a chip ceases to function, a “post mortem” examination of the tissue is completed. This approach enables the platform to be utilized not only for acute but also chronic evaluation of drugs non-invasively for periods of up to several months depending on the system.
Because of our holistic approach to the process of pre-clinical evaluation, more subtle effects, not just cell death, can be detected in our system.
This use of functional readouts reduces the number and frequency of biomarker assays which reduces costs and increases efficiency during pre-clinical evaluations.
Our platform can target rare diseases (of the over 7,000 known rare diseases, approximately 95 percent have no treatment because of a lack of animal models).
We have licensed patents from Cornell University and the University of Central Florida to support our systems.
We have successfully completed projects with 15 commercial clients, including Roche, AstraZeneca, L’Oreal, Sanofi and several others, the results of which are detailed in high impact journals.
The Sanofi project provided efficacy data for an investigational new drug application to the FDA which enabled the authorization of a clinical trial.
| Country | United States |
| Founded | 2015 |
| Industry | Health Care |
| Sector | Life Sciences Tools & Services |
| Employees | 27 |
| CEO | James F. Kronauge, Jr., Ph.D. |
Contact Details
Address: 12501 Research Parkway Suite 100 Orlando, FL 32826 United States | |
| Phone | (407) 900-5915 |
| Website | hesperosinc.com |
Stock Details
| Ticker Symbol | HESP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907702 |
| Employer ID | 47-2107365 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| James F. Kronauge, Jr., Ph.D. | Chief Executive Officer |
| Kenneth D. Najour, DBA, CPA | Chief Financial Officer |
| Michael L. Shuler, Ph.D. | President and Director |
| James J. Hickman, Ph.D. | Chief Scientist and Chairman of the Board |
| Gilberto M. Villacorta, Ph.D. | Vice President and Secretary |
| Antonio Marra, Jr. | Director |
| James Stanker | Director |
| Kathryn O’Connor Gardner | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 13, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 16, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 14, 2022 | DRS | [Cover] Draft Registration Statement |